Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Income from Continuing Operations (2020 - 2026)

Immuneering's Income from Continuing Operations history spans 7 years, with the latest figure at 13974630.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 7.12% to 13974630.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 55265061.0, a 10.87% increase, with the full-year FY2025 number at 56336563.0, up 8.36% from a year prior.
  • Income from Continuing Operations came in at 13974630.0 for Q1 2026, down from 11891675.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 11503250.0 in Q2 2022, with the low at 18142915.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 13960329.12 across 5 years, with a median of 13974630.0 in 2026.
  • Biggest five-year swings in Income from Continuing Operations: crashed 105.36% in 2022 and later surged 34.46% in 2025.
  • Year by year, Income from Continuing Operations stood at 13468839.0 in 2022, then decreased by 15.44% to 15547844.0 in 2023, then dropped by 16.69% to 18142915.0 in 2024, then surged by 34.46% to 11891675.0 in 2025, then decreased by 17.52% to 13974630.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for IMRX at 13974630.0 in Q1 2026, 11891675.0 in Q4 2025, and 14964875.0 in Q3 2025.